April 11, 2024: Ozempic Lawsuit Joint Defense Statement Filed by Novo Nordisk and Eli Lilly Defendants Novo Nordisk and Eli Lilly have submitted a joint statement of the case in the ongoing Ozempic lawsuit
Consult Pharm (2016) 31:68597
Certain polyphenol-rich foods have shown promise in preliminary research: Green tea contains catechins that may influence metabolic pathways Berries (blueberries, strawberries, blackberries) provide anthocyanins with potential metabolic benefits Turmeric (curcumin) has been investigated for effects on glucose metabolism It is crucial to emphasise that while these foods may support natural GLP-1 production, there is no official link established between consuming specific foods and clinically significant increases in GLP-1 comparable to pharmaceutical treatments
Keep the final call tied to your own labs, history, medications, and clinician guidance
Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis
Preda et al (2023) : Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery This research involved the study of 100 patients who underwent routine gastroscopy before sleeve gastrectomy
